1. Home
  2. AIIO vs CRDL Comparison

AIIO vs CRDL Comparison

Compare AIIO & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robo.ai Inc. Class B Ordinary Shares

AIIO

Robo.ai Inc. Class B Ordinary Shares

N/A

Current Price

$0.13

Market Cap

106.6M

Sector

Industrials

ML Signal

N/A

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$1.08

Market Cap

97.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIIO
CRDL
Founded
N/A
2017
Country
United Arab Emirates
Canada
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.6M
97.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
AIIO
CRDL
Price
$0.13
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
5.2M
312.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.77
52 Week High
$2.82
$1.59

Technical Indicators

Market Signals
Indicator
AIIO
CRDL
Relative Strength Index (RSI) 35.51 59.91
Support Level $0.11 $0.95
Resistance Level $0.18 $1.10
Average True Range (ATR) 0.02 0.04
MACD 0.01 0.00
Stochastic Oscillator 30.15 88.74

Price Performance

Historical Comparison
AIIO
CRDL

About AIIO Robo.ai Inc. Class B Ordinary Shares

Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: